Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19

Summary

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally.

Given no specific antiviral therapy for CoVID-19 infection and the availability of Yinhu Qingwen Decoction as a potential antiviral Chinese medicine based on vivo antiviral studies in CoVID-19, this randomized,three-arm controlled, single-blind trial will evaluate the efficacy and safety of Yinhu Qingwen Decoction (Granula) in patients hospitalized with mild or common CoVID-19 respiratory disease.

Conditions

• CoVID-19
• Chinese Medicine

Interventions

DRUG

YinHu QingWen Decoction

YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.

DRUG

YinHu QingWen Decoction(low dose)

This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.

OTHER

Chinese medicine treatment

This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.

OTHER

standard western medicine treatment

Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.

Sponsors & Collaborators

• China Academy of Chinese Medical Sciences

  lead OTHER

Principal Investigators

• Wei Zhang · Jingzhou Hospital of Traditional Chinese Medicine

• Jiang-Rong Huang, M.D. · Yangtze University Health Science Center

• Xiao-Dong Li, M.D. · Hubei Hospital of Traditional Chinese Medicine

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-10-31

Primary Completion

2022-12-31

Completion

2023-05-31

Countries

• China

Study Locations